Understanding how p53 and Mdm2 proteins work in normal and cancer cells
Functions and Activities of p53 and Mdm2 in Normal and Cancer Cells
This study is looking at how two important proteins, p53 and Mdm2, work together in both healthy and cancer cells to help us understand how they might be used to create new cancer treatments that could benefit patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia Univ New York Morningside NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10897964 on NIH RePORTER |
What this research studies
This research investigates the roles of the p53 protein, a key cancer suppressor, and its regulator Mdm2 in both healthy and cancerous cells. By exploring how these proteins interact and control cellular processes like cell death and DNA repair, the research aims to identify new therapeutic strategies for cancer treatment. The study employs advanced techniques, including CRISPR, to manipulate these proteins and assess their effects on cancer cells. Patients may benefit from insights that could lead to the development of new drugs targeting these proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that retain wild-type p53 or those who may benefit from therapies targeting Mdm2.
Not a fit: Patients with cancers that do not express p53 or have mutations in the p53 gene may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance the effectiveness of cancer therapies by targeting the p53 and Mdm2 proteins.
How similar studies have performed: Previous research has shown promising results in targeting the p53-Mdm2 interaction, indicating potential for success in this area.
Where this research is happening
New York, United States
- Columbia Univ New York Morningside — New York, United States (Active)
Researchers
- Principal investigator: Prives, Carol — Columbia Univ New York Morningside
- Study coordinator: Prives, Carol
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.